AG-519: Additional Ph I data

Data from 40 healthy volunteers in the second part of a 3-part, double-blind, U.K. Phase I trial showed that twice-daily 10-375 mg doses of oral AG-519 for 14 days reduced mean blood 2,3-diphosphoglyc...